NEUCHATEL, Switzerland, February 2, 2011 /PRNewswire/ -- Elsevier Properties SA announces the launch of the 2011 Reaxys PhD Prize, a global competition for candidates currently studying for a PhD or having completed a PhD within the last 12 months.
The prize will be awarded for original and innovative research in organic, organometallic and inorganic chemistry to the candidates that demonstrate excellence in methodology and approach in a peer-reviewed publication. Three prize winners will each receive a check for $2000 and be invited to present their research at the Winners' Symposium, to be held during the 14th Asian Chemical Congress, 5 - 8 September, 2011 in Bangkok, Thailand.
David Evans PhD, Scientific Affairs Director at Elsevier Properties SA said, "The Reaxys PhD Prize celebrates innovation and creativity in chemistry research from around the world, values which lie at the heart Reaxys itself." He continued, "In 2010 we received over 300 submissions from around the world covering the breadth of modern chemistry including representatives from most of the leading chemistry universities. The quality of research was outstanding, and the finalists and winners are clearly at the cutting edge of chemistry research. A high bar has been set for 2011."
All entries will be evaluated by a review board of leading international chemists, chaired by the following members of the Reaxys Advisory Board:
- Professor A. G. M. Barrett - Imperial College London, UK - Professor B. M. Trost - Stanford University, USA - Professor H. N. C. Wong - Chinese University of Hong Kong, China
Submissions will be reviewed based upon originality, innovation, importance to the field, applicability, rigor of approach and publication quality.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by February 28, 2011 at the Reaxys PhD Prize website: http://prize.reaxys.com
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys(R), PharmaPendium(TM) and The Lancet(R) are owned and protected by Elsevier Properties SA and used under license. For additional information see http://www.reedelsevier.com.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell (http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD Consult (http://www.mdconsult.com/) and Nursing Consult ( http://www.nursingconsult.com/), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review (http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com/), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact Harald Boersma +31-20-485-27-36 firstname.lastname@example.org